查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403496

感覺異常治療市場至2030年的預測：按類型、治療方法、原因、分銷管道、最終用戶和地區的全球分析

Paresthesia Treatment Market Forecasts to 2030 - Global Analysis By Type, Treatment, Cause, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球感覺異常治療市場規模為 53.9 億美元，預計在預測期內年複合成長率為 5.6%，到 ​​2030年將達到 78.9 億美元。

感覺異常治療市場是指涵蓋診斷、管理和緩解感覺異常（麻木、麻痺、灼熱感等異常感覺為特徵的神經系統疾病）症狀為目的的各種產品和服務的經濟領域。提供多種治療方案，包括藥物、神經調節劑和復健療法，以緩解麻木症狀及其根本原因。

根據世界衛生組織（WHO）預測，2020年60歲以上人口預計將達到約10億，2030年將超過14億。

慢性病增加

隨著糖尿病、神經病變和自體免疫疾病等慢性疾病的日益流行，以刺痛和麻木等異常感覺為特徵的感覺異常的發生率也相應增加。感覺異常通常是潛在醫療問題的症狀，增加了對有效治療方法和管理策略的需求。此外，醫療保健提供者被迫應對越來越多尋求緩解與感覺障礙相關的不適的患者，推動了治療市場的擴張。

某些治療方法可能產生的副作用

神經刺激和藥物治療等干涉措施可能會導致某些患者出現不良反應、不適和併發症。因此，對安全性和耐受性的擔憂可能會限制患者和醫生的接受度，並可能阻止這些治療方法的廣泛使用。然而，個體對治療的反應各不相同，醫療保健提供者面臨著仔細評估和為每位患者量身定做干涉措施的挑戰。

對神經調節治療的需求不斷成長

神經調節包括脊髓刺激和周邊神經刺激等多種程序，已成為治療感覺麻痺和相關神經病變的有效方法。隨著神經病變和脊椎疾病等慢性疾病的盛行率不斷增加，治療性介入的需求不斷成長。神經調節技術提供客製化的微創解決方案，當傳統治療方法被認為不足時，為患者提供可行的替代方案。

與目前治療方法相關的負面結果

目前治療方法可能產生的副作用和併發症對麻醉治療市場構成嚴重威脅。麻木的治療方法可能會帶來感染、設備故障和無意的神經損傷等風險，包括脊髓刺激和藥物治療。然而，替代療法和新興市場技術的開拓可能會威脅現有治療方法的市場力量。為了在不斷變化的感覺障礙治療市場中減輕這些風險，保持當前策略的安全性和有效性並繼續創新非常重要。

COVID-19 的影響：

感覺異常治療市場受到了 COVID-19 大流行的嚴重影響。由於醫療保健服務中斷、供應鏈問題以及重點轉向流行病管理，麻醉藥物的創造和普及已經放緩。然而，對遠端醫療和遠端患者監護的日益重視為線上諮詢和家庭治療提供了機會。隨著醫療保健行業在技術發展和常規護理回歸的推動下適應新常態，預計將逐步復甦。

預計慢性感覺障礙產業在預測期內將是最大的

慢性感覺異常細分市場預計將成長最大佔有率。隨著糖尿病、週邊神經病變和自體自體免疫疾病等慢性疾病在全球的盛行率不斷上升，越來越多的人遭受持續性和復發性感覺障礙。慢性感覺異常的特徵是長期或反覆出現異常感覺，例如刺痛或麻木，需要持續有效的治療策略。此外，這種日益普遍的現象刺激了對有針對性的持久解決方案的需求，並促進了慢性感覺麻木的蔓延。

預計零售藥局領域在預測期內年複合成長率最高

零售藥房業務預計將保持良好成長。隨著對麻木和相關神經系統疾病的認知不斷增強，人們尋求更容易獲得和方便的方法來獲得治療和藥物。零售藥局是各種藥物的重要分銷點，包括緩解麻木症狀的藥物。零售藥局可以方便地獲得成藥藥和處方藥，使廣大患者可以獲得感覺異常的治療。

比例最高的地區：

在中國、印度和日本等國家，慢性病盛行率不斷上升，人口迅速老化，導致與感覺障礙相關的疾病發生率上升，感覺障礙治療市場顯著成長。人們對神經系統疾病及其治療的認知不斷提高，增加了該地區對有效感覺障礙治療的需求。此外，醫療基礎設施的發展、積極的政府措施以及醫療支出的快速成長也促進了該地區的市場成長。

年複合成長率最高的地區：

歐洲地區在預測期內快速成長，因為該地區的法規環境支持技術創新並鼓勵神經病學和神經調節領域的研發活動。醫療保健投資的迅速增加以及對以患者為中心的護理的重視，使歐洲成為感覺障礙治療方法進展的中心。由於醫療技術的進步、醫療保健支出的增加和意識的提高，該市場不斷成長。此外，製藥公司和醫療保健提供者之間的區域合作加速研究和開發工作，並在該地區創造新的治療選擇。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球感覺異常治療市場：依類型

  • 慢性感覺異常
  • 急性感覺異常
  • 其他類型

第6章 全球感覺異常治療市場：依治療分類

  • Tropical Creams
    • Prilocaine
    • 利多卡因
    • 其他Tropical Creams
  • 抗驚厥藥
  • 免疫抑制劑
    • 靜脈注射丙種球蛋白
    • Prednisone
    • 其他免疫抑制劑
  • 抗病毒藥物
  • 其他治療方法

第7章 全球感覺異常治療市場：依原因分類

  • 神經受壓迫
  • 神經損傷
  • 代謝紊亂
  • 其他原因

第8章 全球感覺異常治療市場：按分銷管道

  • 零售藥房
  • 醫院藥房
  • 網路藥房
  • 直接競標
  • 其他分銷管道

第9章 全球感覺異常治療市場：依最終用戶分類

  • 診所
  • 居家護理
  • 診斷中心
  • 其他最終用戶

第10章 全球感覺異常治療市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Abbott Laboratories
  • AstraZeneca
  • Baxter International Inc.
  • Boston Scientific Corporation
  • Cipla Ltd
  • ElectroCore LLC
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Nevro Corp
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stimwave LLC
  • Stryker Corp
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC24721

According to Stratistics MRC, the Global Paresthesia Treatment Market is accounted for $5.39 billion in 2023 and is expected to reach $7.89 billion by 2030 growing at a CAGR of 5.6% during the forecast period. The Paresthesia Treatment Market refers to the economic domain encompassing the various products and services aimed at diagnosing, managing, and alleviating symptoms of paresthesia-a neurological condition characterized by abnormal sensations such as tingling, numbness, and burning. It provides a spectrum of therapeutic options, including pharmaceuticals, neuromodulation devices, and rehabilitation therapies, tailored to alleviate the symptoms of paresthesia and its underlying causes.

According to the World Health Organization, the number of people aged over 60 years and above was around 1 billion in 2020 and is projected to reach over 1.4 billion people by 2030.

Market Dynamics:

Driver:

Increasing incidences of chronic illnesses

As chronic conditions such as diabetes, neuropathy, and autoimmune disorders become more widespread, the incidence of paresthesia, characterized by abnormal sensations like tingling and numbness, has witnessed a proportional rise. Paresthesia often manifests as a symptom of underlying medical issues, prompting an increased demand for effective treatments and management strategies. Additionally, healthcare providers are compelled to address the growing patient pool seeking relief from paresthesia-related discomfort, fostering the expansion of the treatment market.

Restraint:

Possibility of adverse effects linked to specific treatment modalities

Certain patients may have negative reactions, discomfort, or complications from interventions like nerve stimulation or medication therapy. This may prevent these treatments from being widely used because patient and physician acceptance may be restricted due to worries about safety and tolerability. However, it is challenging because individual responses to treatments vary, so healthcare providers must carefully evaluate and customize interventions for each patient.

Opportunity:

Increasing need for neuromodulation treatments

Neuromodulation, encompassing various techniques such as spinal cord stimulation and peripheral nerve stimulation, has gained prominence as an effective approach in managing paresthesia and associated neurological disorders. With an increasing prevalence of chronic conditions like neuropathy and spinal disorders, there is a growing demand for advanced therapeutic interventions that directly target the nervous system to alleviate symptoms like tingling and numbness. Neuromodulation techniques offer a tailored and minimally invasive solution, providing patients with a viable alternative when traditional treatments prove insufficient.

Threat:

Negative consequences related to current treatment methods

The possibility of negative side effects and complications from current treatment modalities poses a serious threat to the paresthesia treatment market. Treatments for paresthesia that involve risks like infection, device malfunction, or unintentional nerve damage include spinal cord stimulation and medications. However, the market dominance of existing treatments may be threatened by developments in alternative therapies or emerging technologies. In order to lessen these risks in the ever-changing paresthesia treatment market, it will be essential to maintain the safety and effectiveness of current strategies and to consistently innovate.

COVID-19 Impact:

The paresthesia treatment market has been severely impacted by the COVID-19 pandemic. The creation and uptake of paresthesia treatments have slowed down as a result of disruptions in healthcare services, issues with the supply chain, and a shift in focus toward pandemic management. However, opportunities for online consultations and at-home treatments have been made possible by the growing emphasis on telemedicine and remote patient monitoring. It is anticipated to progressively rebound as the healthcare industry adjusts to the new normal, propelled by technological developments and the return of routine medical care.

The chronic paresthesia segment is expected to be the largest during the forecast period

The chronic paresthesia segment is expected to grow at a largest share. With a rising global incidence of chronic health conditions such as diabetes, peripheral neuropathy, and autoimmune disorders, a growing population is experiencing persistent and recurrent paresthesia. Chronic paresthesia, characterized by long-term or recurring abnormal sensations like tingling and numbness, necessitates sustained and effective treatment strategies. Moreover, this increasing prevalence has fueled a demand for targeted and enduring solutions, driving the expansion of the chronic paresthesia.

The retail pharmacy segment is expected to have the highest CAGR during the forecast period

Retail Pharmacy segment is projected to hold lucrative growth. As awareness about paresthesia and related neurological disorders increases, individuals seek accessible and convenient avenues for obtaining treatment and medications. Retail pharmacies serve as crucial distribution points for a wide array of pharmaceutical products, including those designed to alleviate symptoms of paresthesia. The ease of access to over-the-counter medications and prescription drugs at retail pharmacies enhances the availability of paresthesia treatments to a broad spectrum of patients.

Region with largest share:

Due to increasing prevalence of chronic diseases, coupled with a rapidly growing aging population in countries like China, India, and Japan, has led to a rising incidence of paresthesia-related conditions, the Asia-Pacific paresthesia treatment market has grown substantially. As awareness about neurological disorders and their management improves, there is a heightened demand for effective paresthesia treatments in the region. Additionally, the evolving healthcare infrastructure, favorable government initiatives, and a surge in healthcare spending contribute to the market's growth in the region.

Region with highest CAGR:

As the region's regulatory environment supports innovation, encouraging research and development activities in the field of neurology and neuromodulation, Europe region is growing at a rapid pace over the projected period. A surge in healthcare investments, coupled with a strong focus on patient-centric care, positions Europe as a hub for advancements in paresthesia treatment modalities. The market has grown as a result of medical technology advancements, increased healthcare spending, and growing awareness. Furthermore, research and development efforts have been fueled by regional partnerships between pharmaceutical companies and healthcare providers, which have resulted in novel treatment options in the region.

Key players in the market:

Some of the key players in Paresthesia Treatment market include Abbott Laboratories, AstraZeneca, Baxter International Inc., Boston Scientific Corporation, Cipla Ltd, ElectroCore LLC, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mylan N.V, Nevro Corp, Novartis AG, Pfizer Inc., Sanofi, Stimwave LLC, Stryker Corp and Teva Pharmaceutical Industries Ltd.

Key Developments:

In December 2023, AstraZeneca Pharma India Ltd. has signed a memorandum of understanding (MoU) with Roche Diagnostics India to improve diagnostics for breast cancer patients with a key focus to streamlining HER2 diagnostics with newer advancements in the field. As per the partnership, comprehensive training initiatives for pathologists and medical oncologists will be imparted. Training modules designed for oncologists will cover advances in HER-2 testing and HER-2 low interpretations.

In September 2023, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years.

Types Covered:

  • Chronic Paresthesia
  • Acute Paresthesia
  • Other Types

Treatments Covered:

  • Tropical Creams
  • Anticonvulsants
  • Immunosuppressant
  • Antivirals
  • Other Treatments

Causes Covered:

  • Nerve Compression
  • Nerve Damage
  • Metabolic Disorders
  • Other Causes

Distribution Channels Covered:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy
  • Direct Tenders
  • Other Distribution Channels

End Users Covered:

  • Clinics
  • Homecare
  • Diagnosis Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Paresthesia Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Chronic Paresthesia
  • 5.3 Acute Paresthesia
  • 5.4 Other Types

6 Global Paresthesia Treatment Market, By Treatment

  • 6.1 Introduction
  • 6.2 Tropical Creams
    • 6.2.1 Prilocaine
    • 6.2.2 Lidocaine
    • 6.2.3 Other Tropical Creams
  • 6.3 Anticonvulsants
  • 6.4 Immunosuppressant
    • 6.4.1 Intravenous Gamma Globulin
    • 6.4.2 Prednisone
    • 6.4.3 Other Immunosuppressants
  • 6.5 Antivirals
  • 6.6 Other Treatments

7 Global Paresthesia Treatment Market, By Cause

  • 7.1 Introduction
  • 7.2 Nerve Compression
  • 7.3 Nerve Damage
  • 7.4 Metabolic Disorders
  • 7.5 Other Causes

8 Global Paresthesia Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Hospital Pharmacy
  • 8.4 Online Pharmacy
  • 8.5 Direct Tenders
  • 8.6 Other Distribution Channels

9 Global Paresthesia Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Clinics
  • 9.3 Homecare
  • 9.4 Diagnosis Centers
  • 9.5 Other End Users

10 Global Paresthesia Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 AstraZeneca
  • 12.3 Baxter International Inc.
  • 12.4 Boston Scientific Corporation
  • 12.5 Cipla Ltd
  • 12.6 ElectroCore LLC
  • 12.7 Eli Lilly and Company
  • 12.8 GlaxoSmithKline plc
  • 12.9 Johnson & Johnson Services, Inc.
  • 12.10 Merck & Co., Inc.
  • 12.11 Mylan N.V
  • 12.12 Nevro Corp
  • 12.12 Novartis AG
  • 12.14 Pfizer Inc.
  • 12.15 Sanofi
  • 12.16 Stimwave LLC
  • 12.17 Stryker Corp
  • 12.18 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Paresthesia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 2 Global Paresthesia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Paresthesia Treatment Market Outlook, By Chronic Paresthesia (2021-2030) ($MN)
  • Table 4 Global Paresthesia Treatment Market Outlook, By Acute Paresthesia (2021-2030) ($MN)
  • Table 5 Global Paresthesia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 6 Global Paresthesia Treatment Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 7 Global Paresthesia Treatment Market Outlook, By Tropical Creams (2021-2030) ($MN)
  • Table 8 Global Paresthesia Treatment Market Outlook, By Prilocaine (2021-2030) ($MN)
  • Table 9 Global Paresthesia Treatment Market Outlook, By Lidocaine (2021-2030) ($MN)
  • Table 10 Global Paresthesia Treatment Market Outlook, By Other Tropical Creams (2021-2030) ($MN)
  • Table 11 Global Paresthesia Treatment Market Outlook, By Anticonvulsants (2021-2030) ($MN)
  • Table 12 Global Paresthesia Treatment Market Outlook, By Immunosuppressant (2021-2030) ($MN)
  • Table 13 Global Paresthesia Treatment Market Outlook, By Intravenous Gamma Globulin (2021-2030) ($MN)
  • Table 14 Global Paresthesia Treatment Market Outlook, By Prednisone (2021-2030) ($MN)
  • Table 15 Global Paresthesia Treatment Market Outlook, By Other Immunosuppressants (2021-2030) ($MN)
  • Table 16 Global Paresthesia Treatment Market Outlook, By Antivirals (2021-2030) ($MN)
  • Table 17 Global Paresthesia Treatment Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 18 Global Paresthesia Treatment Market Outlook, By Cause (2021-2030) ($MN)
  • Table 19 Global Paresthesia Treatment Market Outlook, By Nerve Compression (2021-2030) ($MN)
  • Table 20 Global Paresthesia Treatment Market Outlook, By Nerve Damage (2021-2030) ($MN)
  • Table 21 Global Paresthesia Treatment Market Outlook, By Metabolic Disorders (2021-2030) ($MN)
  • Table 22 Global Paresthesia Treatment Market Outlook, By Other Causes (2021-2030) ($MN)
  • Table 23 Global Paresthesia Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 24 Global Paresthesia Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 25 Global Paresthesia Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 26 Global Paresthesia Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 27 Global Paresthesia Treatment Market Outlook, By Direct Tenders (2021-2030) ($MN)
  • Table 28 Global Paresthesia Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 29 Global Paresthesia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 Global Paresthesia Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 31 Global Paresthesia Treatment Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 32 Global Paresthesia Treatment Market Outlook, By Diagnosis Centers (2021-2030) ($MN)
  • Table 33 Global Paresthesia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.